Mouth health study for hepatitis B and D patients
Treatments studied
Part of Digestive system, Infections, Mouth & dental clinical trials.
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have hepatitis B and D together (confirmed by a doctor)
- You are either taking bulevirtide or not taking it (both groups are needed)
- You do not have other health problems that affect your gums, like uncontrolled diabetes or autoimmune diseases
- You are not pregnant or nursing
- You have not had mouth or gum surgery in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
Hear when a new Hepatitis D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.